Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog

Celsion CorporationCLSN was up approximately 18.6% after the company announced encouraging interim data from its ongoing open-label phase II DIGNITY study on ThermoDox for recurrent chest wall (RCW) breast cancer.

The study is evaluating ThermoDox in combination with mild hyperthermia. Based on available data, 67% of patients experienced a clinical benefit of their highly refractory disease with a local response rate of 58% observed in the 12 evaluable patients. Additionally, 5 patients experienced complete responses, 2 partial responses and 1 stable disease. The company expects to complete enrollment in the DIGNITY study in the third quarter of 2015. The study is expected to be completed later this year.

Based on data from the DIGNITY study, the company expects to initiate the Euro-DIGNITY study later this quarter. The Euro-DIGNITY study will evaluate the use of ThermoDox and hyperthermia in patients suffering from RCW breast cancer. Data from the study, if positive, will enable the company to submit regulatory application in Europe.

We note that Celsion has a license and distribution agreement with myTomorrows to implement an Early Access Program (EAP) for ThermoDox in the EU and Switzerland for the treatment of RCW breast cancer patients. The company expects ThermoDox to be available shortly for sales at commercial prices to physicians who are treating patients with limited therapeutic options.

The company is also evaluating ThermoDox for the treatment of primary liver cancer (phase III).

Celsion carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care space are Cytokinetics, Incorporated CYTK , Valeant Pharmaceuticals International, Inc. VRX and Affymetrix Inc. AFFX . While Valeant and Affymetrix hold a Zacks Rank #1 (Strong Buy), Cytokinetics is a Zacks Rank #2 (Buy) stock.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

VALEANT PHARMA (VRX): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

CELSION CORP (CLSN): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More